Abstract：Objective To investigate the application effect of different doses of Dopamine receptor agonist s in the treatment of Parkinson′s disease. Methods A total of 66 patients with Parkinson′s disease admitted to Anshan cancer hospital from September 2017 to September 2019 were selected as the research objects and divided into the control group and the observation group according to the dynamic random grouping method，with 33 cases in each group. The control group was treated with low-dose Dopamine receptor agonist (Pramipexole Hydrochloride Tablets) and the observation group was treated with high-dose Pramipexole Hydrochloride Tablets. The results of unified Parkinson′s disease rating scale (UPDRSDI) and the medical outcomes study 36-item short-form health survey (SF-36) scores were compared between the two groups. Results At the 4th，8th and 12th week of treatment，UPDRSDI scores of the observation group were lower than those of the control group，and the differences were statistically significant (P＜0.05). After treatment，the SF-36 score of the observation group was higher than that of the control group，the difference was statistically significant (P＜0.05). Conclusion Dopamine agonists have a significant effect in the treatment of Parkinson′s disease，and the effect varies with the dose. The use of large doses will improve the clinical treatment effect，so the clinical application should be evaluated based on the actual condition of patients.
安娜. 不同剂量多巴胺受体激动剂在帕金森病治疗中的应用效果[J]. 中国当代医药, 2022, 29(1): 101-103.
AN Na. Application effect of different doses of Dopamine agonists in the treatment of Parkinson′s disease. 中国当代医药, 2022, 29(1): 101-103.
Kostadinov I，Mihaylova A，Zlatanova H，et al.Influence of the dopamine receptor agonist pramipexole on serum levels of pro-and antiinflammatory cytokines[J].Eur Neuropsychopharmacol，2019，29（6）：S293-S294.
[5]
Paudel P，Park SE，Seong SH，et al.Bromophenols from Symphyocladia latiuscula Target Human Monoamine Oxidase and Dopaminergic Receptors for the Management of Neurodegenerative Diseases[J].J Agric Food Chem，2020，68（8）：2426-2436.
[7]
Glaser T，Andrejew R，Oliveira-Giacomelli á，et al.Purinergic Receptors in Basal Ganglia Diseases：Shared Molecular Mechanisms between Huntington′s and Parkinson′s Disease[J].Neurosci Bull，2020，36（11）：1299-1314.
[8]
Schneider A，Sari AT，Alhaddad H，et al.Overview of Therapeutic Drugs and Methods for the Treatment of Parkinson′s Disease[J].CNS Neurol Disord Drug Targets，2020，19（3）：195-206.
京公网安备 11010502046607号